CLOROTEKAL (chloroprocaine hydrochloride) by B. Braun is clinical pharmacology chloroprocaine, like other local anesthetics, blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential. First approved in 2017.
Drug data last refreshed 33m ago · AI intelligence enriched 6d ago
CLOROTEKAL (chloroprocaine hydrochloride) is a rapid-onset local anesthetic administered via intrathecal injection that blocks nerve impulse generation and conduction. It is used for regional anesthesia in surgical and procedural settings, with onset typically within 6–12 minutes and duration up to 60 minutes. The drug works by increasing the threshold for electrical excitation in nerves, slowing impulse propagation, and reducing action potential rise rate.
Product is at peak commercialization stage with stable market positioning; team size likely optimized for maintenance rather than expansion.
CLINICAL PHARMACOLOGY Chloroprocaine, like other local anesthetics, blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the…
Worked on CLOROTEKAL at B. Braun? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparison of Clorotekal and Bupivacaine for Short Obstetric Surgery
Impact of Chloroprocaine (CLOROTEKAL®) on Eligibility for Discharge From Hospital After Outpatient Surgery
Observational Study on 2-chloroprocaine Hydrochloride 1%
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CLOROTEKAL offers a stable, mature product opportunity in a specialized anesthesia segment with minimal job openings currently reported. Career value lies in mastering hospital/surgical center relationships, formulary management, and procedural-based selling in a non-growth but predictable market.